SAN DIEGO --(BUSINESS WIRE)--Jun. 28, 2021-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will be added to the Russell Microcap Index after the U.S. market opens today, June 28, 2021 .
Expands company’s patent portfolio in pursuit of worldwide intellectual property protection for proprietary technology that detects biomarkers in tissue, blood, and cerebrospinal fluid SAN DIEGO --(BUSINESS WIRE)--Jul. 6, 2021-- Biocept, Inc . (NASDAQ: BIOC), a leading provider of molecular
SAN DIEGO --(BUSINESS WIRE)--Jul. 19, 2021-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall , President and CEO, will participate at the following investment conferences: Brookline Capital Markets Newport
Expanded Board to build on company’s recent successes in oncology diagnostics and COVID-19 testing SAN DIEGO --(BUSINESS WIRE)--Jul. 20, 2021-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, has appointed Linda Rubinstein and Antonino Morales to
Reimbursement decision expands access to testing that provides critical information used to guide targeted treatment options for patients with breast cancer Company provides updates on other initiatives including CNSide™, its proprietary test for neuro-oncology, and COVID-19 testing volume, which
SAN DIEGO --(BUSINESS WIRE)--Aug. 3, 2021-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, has appointed David Karlander as Senior Vice President of Commercial Operations. With more than 25 years of industry experience, Karlander will lead all
SAN DIEGO --(BUSINESS WIRE)--Aug. 9, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will release financial results for the three and six months ended June 30, 2021 after the market closes on Monday, August 16, 2021 .
Second quarter revenues of $12.0 million driven by RT-PCR COVID-19 testing Continued sequential-quarter CNSide™ volume growth with customer base expanding to more than 30 leading U.S. academic institutions, including multiple repeat users Issued coverage with high-value payment by Medicare for the
Study to be presented at the Society for Neuro-Oncology Third Annual Conference on Brain Metastases, Aug. 19-20 SAN DIEGO --(BUSINESS WIRE)--Aug. 19, 2021-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, today announced that new data show the company’s
SAN DIEGO --(BUSINESS WIRE)--Aug. 31, 2021-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, today announced that it has granted inducement stock options to purchase an aggregate of 220,800 shares of its common stock to 16 new employees.
